Emcure Pharmaceuticals has achieved a significant milestone by becoming the first Indian company to exclusively distribute and commercialize Poviztra®, Novo Nordisk's semaglutide injection for weight management across India. The company announced the commercial launch, marking an important step in expanding access to advanced weight management therapies in the Indian market.

Product Specifications and Availability

Poviztra® is available in a comprehensive range of strengths delivered through a state-of-the-art pen device system. The product specifications are detailed below:

Clinical Evidence and Global Experience

Semaglutide injection is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes, demonstrating robust real-world use. The molecule has established a strong global presence with nearly a decade of market experience, 38 million patient-years of exposure, and a comprehensive safety and efficacy profile backed by clinical data.

In clinical trials, the semaglutide formulation achieved weight loss of more than 20.00% in many patients, establishing its effectiveness as a weight management solution.

Medical Indications and Target Population

Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with specific criteria:

Market Impact and Company Leadership

Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, highlighted the significance of addressing India's obesity crisis, noting that the country has nearly 254 million people living with generalized obesity and an additional 351 million living with abdominal obesity. The launch represents an important step in expanding equitable access to scientifically validated weight-management solutions through the company's strong distribution capabilities and pan-India reach.

Obesity is linked to over 230 health complications including cardiovascular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alzheimer's disease. This launch reinforces Emcure Pharmaceuticals' commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of overweight and obesity in India.

Emcure Pharmaceuticals has successfully allotted 7,700 equity shares to eligible employees under its Employee Stock Option Scheme 2013 (Emcure ESOS 2013) on December 16, 2025. The allotment represents the exercise of 7,700 vested options by company employees, demonstrating continued participation in the company's equity incentive program.

Regulatory Approval and Process

The Nomination and Remuneration Committee of the Board of Directors approved the allotment through Resolution by Circulation (No. 4 of 2025-26), which was passed unanimously on December 16, 2025. The decision was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Capital Impact

The allotment has resulted in an increase in the company's issued and paid-up share capital. The following table shows the change in share capital structure:

The increase represents an addition of 7,700 equity shares, each with a face value of ₹10, resulting in a total capital increase of ₹77,000.

Share Rights and Trading

The newly allotted equity shares will rank pari passu in all aspects with the existing equity shares of the company. This means the new shares carry identical rights including voting rights, dividend entitlements, and other shareholder privileges as the existing shares.

Market Information

Emcure Pharmaceuticals Limited trades on both major Indian stock exchanges with the script symbol EMCURE on NSE and script code 544210 on BSE. The company has informed both exchanges about this allotment as part of its regulatory disclosure obligations under SEBI listing regulations.